Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy.
Thorac Cancer
; 10(9): 1841-1845, 2019 09.
Article
en En
| MEDLINE
| ID: mdl-31350945
ABSTRACT
Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial-to-mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin-based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sarcoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Quimioterapia Adyuvante
/
Carcinoma Adenoescamoso
/
Transición Epitelial-Mesenquimal
/
Neoplasias Pulmonares
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Thorac Cancer
Año:
2019
Tipo del documento:
Article
País de afiliación:
Malasia
Pais de publicación:
SG
/
SINGAPORE
/
SINGAPUR
/
SINGAPURA